Anti-CD20 monoclonal antibody therapy in multiple myeloma

British Journal of Haematology

Volumn 141, Issue 2, 2008, Pages 135-148

  Kapoor, Prashant ^a   Greipp, Patricia T ^a   Morice, William G ^a   Rajkumar, S Vincent ^a   Witzig, Thomas E ^a   Greipp, Philip R ^a  

^a MAYO CLINIC   (United States)

Author keywords

CD20+ plasma cells; I 131 tositumomab; Immunotherapy; Rituximab; Y 90 ibritumomab

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN; CD38 MONOCLONAL ANTIBODY; CD40 MONOCLONAL ANTIBODY; CD54 MONOCLONAL ANTIBODY; CD70 MONOCLONAL ANTIBODY; CNTO 328; GAMMA INTERFERON; IBRITUMOMAB TIUXETAN; INTERLEUKIN 6 MONOCLONAL ANTIBODY; MELPHALAN; MONOCLONAL ANTIBODY; RITUXIMAB; THALIDOMIDE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOPENIA; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; FEVER; HEADACHE; HEART ARRHYTHMIA; HEPATITIS B; HUMAN; HYPOTENSION; HYPOXIA; LEUKOENCEPHALOPATHY; LYMPHOCYTOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; MYELODYSPLASIA; MYELOMA CELL; NAUSEA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; RASH; REVIEW; RIGOR; SKIN MANIFESTATION; TUMOR LYSIS SYNDROME; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA;

EID: 40949138516     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07024.x     Document Type: Review

References (120)

1. Alcindor, T., Kimlinger, T. Witzig, T.E. (2006) High expression of CD59 and CD55 on benign and malignant plasma cells. Leukaemia & Lymphoma, 47, 919 921.
2. Bakkus, M.H., Van Riet, I., Van Camp, B. Thielemans, K. (1994) Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. British Journal Haematology, 87, 68 74.
3. Bataille, R., Barlogie, B., Lu, Z.Y., Rossi, J.F., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J. Klein, B. (1995) Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86, 685 691.
4. Bello, C. Sotomayor, E.M. (2007) Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology (American Society of Hematology Education Program 233 242.
5. Berenson, J.R., Vescio, R.A. Said, J. (1998) Multiple myeloma: the cells of origin - a two-way street. Leukemia, 12, 121 127.
6. Bergua, J.M., Cabrera, C., Arteta, E.G. Prieto, J. (2007) Rituximab in CD20 positive multiple myeloma. Leukemia doi:).
7. Billadeau, D., Ahmann, G., Greipp, P. Van Ness, B. (1993) The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. Journal of Experimental Medicine, 178, 1023 1031.
8. Boye, J., Elter, T. Engert, A. (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Annals of Oncology, 14, 520 535.
9. Braylan, R.C., Orfao, A., Borowitz, M.J. Davis, B.H. (2001) Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Cytometry, 46, 23 27.
10. Bringhen, S., Avonto, I., Magarotto, V., Boccadoro, M. Palumbo, A. (2006) Investigational treatments for multiple myeloma. Expert Opinion on Investigational Drugs, 15, 1565 1582.
11. Burton, J.D., Ely, S., Reddy, P.K., Stein, R., Gold, D.V., Cardillo, T.M. Goldenberg, D.M. (2004) CD74 is expressed by multiple myeloma and is a promising target for therapy. Clinical Cancer Research, 10, 6606 6611.
12. Calame, K.L. (2001) Plasma cells: finding new light at the end of B cell development. Nature Immunology, 2, 1103 1108.
13. Campbell, P. Marcus, R. (2003) Monoclonal antibody therapy for lymphoma. Blood Reviews, 17, 143 152.
14. Carlo-Stella, C., Guidetti, A., Di Nicola, M., Longoni, P., Cleris, L., Lavazza, C., Milanesi, M., Milani, R., Carrabba, M., Farina, L., Formelli, F., Gianni, A.M. Corradini, P. (2006) CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Experimental Hematology, 34, 721 727.
15. Carlo-Stella, C., Guidetti, A., Di Nicola, M., Lavazza, C., Cleris, L., Sia, D., Longoni, P., Milanesi, M., Magni, M., Nagy, Z., Corradini, P., Carbone, A., Formelli, F. Gianni, A.M. (2007) IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3. Cancer Research, 67, 3269 3275.
16. Chatterjee, M., Chakraborty, T. Tassone, P. (2006) Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. European Journal of Cancer, 42, 1640 1652.
17. Chen, B.J. Epstein, J. (1996) Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood, 87, 1972 1976.
18. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235 242.
19. Coleman, E.J., Brooks, K.J., Smallshaw, J.E. Vitetta, E.S. (2006) The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines. Journal of Immunotherapy, 1997, 29.
20. Corradini, P., Boccadoro, M., Voena, C. Pileri, A. (1993) Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. Journal of Experimental Medicine, 178, 1091 1096.
21. Cremer, F.W., Goldschmidt, H. Moos, M. (2001) Clonotypic B cells in the peripheral blood of patients with multiple myeloma. Blood, 97, 2913 2914.
22. Davies, F.E., Rawstron, A.C., Pratt, G., O'Connor, S., Su'ut, L., Blythe, D., Fenton, J., Claydon, D., Child, J.A., Jack, A.S. Morgan, G.J. (1999) FICTION-TSA analysis of the B-cell compartment in myeloma shows no significant expansion of myeloma precursor cells. British Journal Haematology, 106, 40 46.
23. Davies, F.E., Rawstron, A.C., Owen, R.G. Morgan, G.J. (2000) Controversies surrounding the clonogenic origin of multiple myeloma. British Journal Haematology, 110, 240 241.
24. Davis, B.H., Holden, J.T., Bene, M.C., Borowitz, M.J., Braylan, R.C., Cornfield, D., Gorczyca, W., Lee, R., Maiese, R., Orfao, A., Wells, D., Wood, B.L. Stetler-Stevenson, M. (2007) 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry. Part B, Clinical Cytometry, 72 (Suppl. 1 S5 S13.
25. Dimopoulos, M.A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N.A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J. Anagnostopoulos, N. (2002) Treatment of Waldenstrom's macroglobulinemia with rituximab. Journal of Clinical Oncology, 20, 2327 2333.
26. Epstein, J. (1997) Myeloma stem cell phenotype. Implications for treatment. Hematology/Oncology Clinics of North America, 11, 43 49.
27. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 4117 4126.
28. Fonseca, R., Blood, E.A., Oken, M.M., Kyle, R.A., Dewald, G.W., Bailey, R.J., Van Wier, S.A., Henderson, K.J., Hoyer, J.D., Harrington, D., Kay, N.E., Van Ness, B. Greipp, P.R. (2002) Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood, 99, 3735 3741.
29. Friedberg, J.W. (2005) Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology (American Society of Hematology Education Program 329 334.
30. Garcia-Sanz, R., Orfao, A., Gonzalez, M., Tabernero, M.D., Blade, J., Moro, M.J., Fernandez-Calvo, J., Sanz, M.A., Perez-Simon, J.A., Rasillo, A. Miguel, J.F. (1999) Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood, 93, 1032 1037.
31. Gasparetto, C., Horwitz, M.E., Gockerman, J.P., de Castro, C.M., Moore, J.O., Smith, C.A., Davis, P., Lassite, M., Houser, L., Chao, N.J. Rizzieri, D. (2004) Campath-1H may have activity in the treatment of multiple myeloma. Blood, 104, 4931 (abstract).
32. Gemmel, C., Cremer, F.W., Weis, M., Witzens, M., Moldenhauer, G., Koniczek, K.H., Imbach, U., Ho, A.D., Moos, M. Goldschmidt, H. (2002) Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Annals of Hematology, 81, 119 123.
33. Gertz, M.A., Rue, M., Blood, E., Kaminer, L.S., Vesole, D.H. Greipp, P.R. (2004) Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leukaemia & Lymphoma, 45, 2047 2055.
34. Ghobrial, I.M., Fonseca, R., Greipp, P.R., Blood, E., Rue, M., Vesole, D.H. Gertz, M.A. (2004) Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer, 101, 2593 2598.
35. Gorschluter, M., Ziske, C., Glasmacher, A. Schmidt-Wolf, I.G. (2001) Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma. Clinical Cancer Research, 7, 2195 2204.
36. Gozzetti, A., Fabbri, A., Lazzi, S., Bocchia, M. Lauria, F. (2007) Reply to rituximab activity in CD20 positive multiple myeloma. Leukemia doi:).
37. Greipp, P.T., Kapoor, P., Morice, W.G., Witzig, T.E. Greipp, P.R. (2008) Reply to 'rituximab in CD20 positive multiple myeloma' by P Moreau et al. Leukemia, 22, 214 215.
38. Grillo-Lopez, A.J. (2000) Rituximab: an insider's historical perspective. Seminars in Oncology, 27, 9 16.
39. Grossbard, M.L., Lambert, J.M., Goldmacher, V.S., Spector, N.L., Kinsella, J., Eliseo, L., Coral, F., Taylor, J.A., Blattler, W.A., Epstein, C.L. Nadler, L.M. (1993) Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. Journal of Clinical Oncology, 11, 726 737.
40. Guikema, J.E., Hovenga, S., Vellenga, E. Bos, N.A. (2004) Heterogeneity in the multiple myeloma tumor clone. Leukaemia & Lymphoma, 45, 857 871.
41. Guyre, P.M., Morganelli, P.M. Miller, R. (1983) Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. Journal of Clinical Investigation, 72, 393 397.
42. Himmelmann, A., Riva, A., Wilson, G.L., Lucas, B.P., Thevenin, C. Kehrl, J.H. (1997) PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood, 90, 3984 3995.
43. Hofer, S., Hunziker, S., Dirnhofer, S. Ludwig, C. (2003) Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma. British Journal Haematology, 122, 690 691.
44. Hsi, E., Hussein, M.A., Elson, P., Karam, M.A., Andresen, S., Srkalovic, G. Fishleder, A. (2001) Biologic and clinical evaluation of rituxan (RT) in the management of newly diagnosed multiple myeloma (MM) patients (Pts) an update (abstract). Proceedings of the American Society of Clinical Oncology, 21, 299.
45. Hussein, M.A., Berenson, J.R., Niesvizky, R., Munshi, N.C., Harrop, K.L., McDonald, M. Drachman, J.G. (2005) A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma. Blood, 106, 2572 (abstract).
46. Jones, R.J., Matsui, W.H. Smith, B.D. (2004) Cancer stem cells: are we missing the target? Journal of the National Cancer Institute, 96, 583 585.
47. Katzel, J.A., Hari, P. Vesole, D.H. (2007) Multiple myeloma: charging toward a bright future. CA: A Cancer Journal for Clinicians, 57, 301 318.
48. Kawai, S., Yoshimura, Y., Iida, S., Kinoshita, Y., Koishihara, Y., Ozaki, S., Matsumoto, T., Kosaka, M. Yamada-Okabe, H. (2006) Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncology Reports, 15, 361 367.
49. Klein, B., Wijdenes, J., Zhang, X.G., Jourdan, M., Boiron, J.M., Brochier, J., Liautard, J., Merlin, M., Clement, C., Morel-Fournier, B., Lu, Z.Y., Mannoni, P. Bataille, R. (1991) Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood, 78, 1198 1204.
50. Kohler, G. Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495 497.
51. Korte, W., Jost, C., Cogliatti, S., Hess, U. Cerny, T. (1999) Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Annals of Oncology, 10, 1249 1250.
52. Kosmas, C., Stamatopoulos, K., Stavroyianni, N., Zoi, K., Belessi, C., Viniou, N., Kollia, P. Yataganas, X. (2000) Origin and diversification of the clonogenic cell in multiple myeloma: lessons from the immunoglobulin repertoire. Leukemia, 14, 1718 1726.
53. Kumar, S., Kimlinger, T.K., Lust, J.A., Donovan, K. Witzig, T.E. (2003) Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood, 102, 1075 1077.
54. Lalazar, G., Rund, D. Shouval, D. (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. British Journal Haematology, 136, 699 712.
55. Leo, R., Boeker, M., Peest, D., Hein, R., Bartl, R., Gessner, J.E., Selbach, J., Wacker, G. Deicher, H. (1992) Multiparameter analyses of normal and malignant human plasma cells: CD38 + +, CD56 +, CD54 +, cIg+ is the common phenotype of myeloma cells. Annals of Hematology, 64, 132 139.
56. Li, J.L., Liu, Y.R., Chang, Y., Fu, J.Y. Chen, S.S. (2002a) Immunophenotypic characteristics of multiple myeloma cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 10, 226 228.
57. Li, J., Luo, S.K., Xiong, W.J. Zhou, Z.H. (2002b) Combination of thalidomide and rituximab in suppressing myeloma cells in vitro. Ai Zheng, 21, 1324 1327.
58. Lim, S.H., Zhang, Y., Wang, Z., Varadarajan, R., Periman, P. Esler, W.V. (2004) Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency. Blood, 103, 1971 1972.
59. Lin, P., Owens, R., Tricot, G. Wilson, C.S. (2004a) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. American Journal of Clinical Pathology, 121, 482 488.
60. Lin, P., Mahdavy, M., Zhan, F., Zhang, H.Z., Katz, R.L. Shaughnessy, J.D. (2004b) Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Modern Pathology, 17, 1217 1222.
61. Maloney, D.G. (2007) Follicular NHL: From antibodies and vaccines to graft-versus-lymphoma effects. Hematology (American Society of Hematology Education Program 226 232.
62. Maloney, D.G., Donovan, K. Hamblin, T.J. (1999) Antibody therapy for treatment of multiple myeloma. Seminars in Hematology, 36, 30 33.
63. Mateo, G., Castellanos, M., Rasillo, A., Gutierrez, N.C., Montalban, M.A., Martin, M.L., Hernandez, J.M., Lopez-Berges, M.C., Montejano, L., Blade, J., Mateos, M.V., Sureda, A., de la Rubia, J., Diaz-Mediavilla, J., Pandiella, A., Lahuerta, J.J., Orfao, A. San Miguel, J.F. (2005) Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clinical Cancer Research, 11, 3661 3667.
64. Matsuda, I., Mori, Y., Nakagawa, Y., Sawanobori, M., Uemura, N. Suzuki, K. (2005) Close correlations between CD20 expression, a small mature plasma cell morphology and t(11; 14) in multiple myeloma. Rinsho Ketsueki, 46, 1293 1297.
65. Matsui, W., Huff, C.A., Wang, Q., Malehorn, M.T., Barber, J., Tanhehco, Y., Smith, B.D., Civin, C.I. Jones, R.J. (2004) Characterization of clonogenic multiple myeloma cells. Blood, 103, 2332 2336.
66. McEarchern, J.A., McDonagh, C., Ho, A., Tai, Y.T., Francisco, L., Klussman, K., Morris-Tilden, C., Gordon, K., Oflazoglu, E., Kissler, K., Munshi, N., Anderson, K.C., Treon, S.P., Carter, P., Wahl, A.F., Grewal, I.S. Law, C. (2005) A humanized anti-CD70 monoclonal antibody targets CD70-expressing multiple myeloma. Blood, 106, 1591 (abstract).
67. McEarchern, J.A., Oflazoglu, E., Francisco, L., McDonagh, C.F., Gordon, K.A., Stone, I., Klussman, K., Turcott, E., van Rooijen, N., Carter, P., Grewal, I.S., Wahl, A.F. Law, C.L. (2007) Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood, 109, 1185 1192.
68. Mitterer, M., Oduncu, F., Lanthaler, A.J., Drexler, E., Amaddii, G., Fabris, P., Emmerich, B., Coser, P. Straka, C. (1999) The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients. British Journal Haematology, 106, 737 743.
69. Moreau, P., Harousseau, J.L., Wijdenes, J., Morineau, N., Milpied, N. Bataille, R. (2000) A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. British Journal Haematology, 109, 661 664.
70. Moreau, P., Hullin, C., Garban, F., Yakoub-Agha, I., Benboubker, L., Attal, M., Marit, G., Fuzibet, J.G., Doyen, C., Voillat, L., Berthou, C., Ketterer, N., Casassus, P., Monconduit, M., Michallet, M., Najman, A., Sotto, J.J., Bataille, R. Harousseau, J.L. (2006) Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood, 107, 397 403.
71. Moreau, P., Voillat, L., Benboukher, L., Mathiot, C., Dumontet, C., Robillard, N., Herault, O., Garnache, F., Garand, R., Varoqueaux, N., Avet-Loiseau, H., Harousseau, J.L. Bataille, R. (2007) Rituximab in CD20 positive multiple myeloma. Leukemia, 4, 835 836.
72. Musto, P., Carella, A.M. Jr., Greco, M.M., Falcone, A., Sanpaolo, G., Bodenizza, C., Cascavilla, N., Melillo, L. Carella, A.M. (2003) Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. British Journal Haematology, 123, 746 747.
73. Nagy, Z.A., Hubner, B., Lohning, C., Rauchenberger, R., Reiffert, S., Thomassen-Wolf, E., Zahn, S., Leyer, S., Schier, E.M., Zahradnik, A., Brunner, C., Lobenwein, K., Rattel, B., Stanglmaier, M., Hallek, M., Wing, M., Anderson, S., Dunn, M., Kretzschmar, T. Tesar, M. (2002) Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nature Medicine, 8, 801 807.
74. Niscola, P., Del Principe, M.I., Maurillo, L., Venditti, A., Buccisano, F., Piccioni, D., Amadori, S. Del Poeta, G. (2005) Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia, 19, 1840 1841.
75. Ozaki, S., Kosaka, M., Wakatsuki, S., Abe, M., Koishihara, Y. Matsumoto, T. (1997) Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood, 90, 3179 3186.
76. Peacock, C.D., Wang, Q., Gesell, G.S., Corcoran-Schwartz, I.M., Jones, E., Kim, J., Devereux, W.L., Rhodes, J.T., Huff, C.A., Beachy, P.A., Watkins, D.N. Matsui, W. (2007) Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 104, 4048 4053.
77. Pettersson, M., Sundstrom, C., Nilsson, K. Larsson, L.G. (1995) The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Blood, 86, 2747 2753.
78. Pilarski, L.M., Hipperson, G., Seeberger, K., Pruski, E., Coupland, R.W. Belch, A.R. (2000) Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood, 95, 1056 1065.
79. Rajkumar, S.V. Kyle, R.A. (2005) Multiple myeloma: diagnosis and treatment. Mayo Clinic Proceedings, 80, 1371 1382.
80. Rawstron, A.C., Barrans, S.L., Blythe, D., English, A., Richards, S.J., Fenton, J.A., Davies, F.E., Child, J.A., Jack, A.S. Morgan, G.J. (2001) In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression. British Journal Haematology, 113, 794 802.
81. Rawstron, A.C., Laycock-Brown, G., Hale, G., Davies, F.E., Morgan, G.J., Child, J.A., Hillmen, P. Owen, R.G. (2006) CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy. Haematologica, 91, 1577 1578.
82. Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N. Anderson, D.R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, 435 445.
83. Reya, T., Morrison, S.J., Clarke, M.F. Weissman, I.L. (2001) Stem cells, cancer, and cancer stem cells. Nature, 414, 105 111.
84. Riley, J.K. Sliwkowski, M.X. (2000) CD20: a gene in search of a function. Seminars in Oncology, 27, 17 24.
85. Robillard, N., Avet-Loiseau, H., Garand, R., Moreau, P., Pineau, D., Rapp, M.J., Harousseau, J.L. Bataille, R. (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood, 102, 1070 1071.
86. Rossi, J.F., Fegueux, N., Lu, Z.Y., Legouffe, E., Exbrayat, C., Bozonnat, M.C., Navarro, R., Lopez, E., Quittet, P., Daures, J.P., Rouille, V., Kanouni, T., Widjenes, J. Klein, B. (2005) Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplantation, 36, 771 779.
87. Rottenburger, C., Kiel, K., Bosing, T., Cremer, F.W., Moldenhauer, G., Ho, A.D., Goldschmidt, H. Moos, M. (1999) Clonotypic CD20 + and CD19 + B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. British Journal Haematology, 106, 545 552.
88. Ruffini, P.A. Kwak, L.W. (2001) Immunotherapy of multiple myeloma. Seminars in Hematology, 38, 260 267.
89. San Miguel, J.F., Gonzalez, M., Gascon, A., Moro, M.J., Hernandez, J.M., Ortega, F., Jimenez, R., Guerras, L., Romero, M., Casanova, F., Sanz, M.A., Portero, J.A. Orfao, A. (1991) Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. British Journal Haematology, 77, 185 190.
90. Sekimoto, E., Ozaki, S., Ohshima, T., Shibata, H., Hashimoto, T., Abe, M., Kimura, N., Hattori, K., Kawai, S., Kinoshita, Y., Yamada-Okabe, H., Tsuchiya, M. Matsumoto, T. (2007) A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Research, 67, 1184 1192.
91. Shapiro-Shelef, M. Calame, K. (2004) Plasma cell differentiation and multiple myeloma. Current Opinion in Immunology, 16, 226 234.
92. Sharkey, R.M. Goldenberg, D.M. (2006) Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA: A Cancer Journal for Clinicians, 56, 226 243.
93. Sivaraman, S., Venugopal, P., Ranganathan, R., Deshpande, C.G., Huang, X., Jajeh, A., Gregory, S.A., O'Brien, T. Preisler, H.D. (2000) Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines, Cellular & Molecular Therapy, 6, 81 87.
94. Smallshaw, J.E., Coleman, E., Spiridon, C. Vitetta, E.S. (2004) The generation and anti-myeloma activity of a chimeric anti-CD54 antibody, cUV3. Journal of Immunotherapy, 1997, 27.
95. Smith, M.R. (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 22, 7359 7368.
96. Stein, R., Qu, Z., Cardillo, T.M., Chen, S., Rosario, A., Horak, I.D., Hansen, H.J. Goldenberg, D.M. (2004) Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood, 104, 3705 3711.
97. Stein, R., Mattes, M.J., Cardillo, T.M., Hansen, H.J., Chang, C.H., Burton, J., Govindan, S. Goldenberg, D.M. (2007) CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clinical Cancer Research, 13, 5556s 5563s.
98. Stevenson, G.T. (2006) CD38 as a therapeutic target. Molecular Medicine, 12, 345 346.
99. Tai, Y.T., Li, X., Tong, X., Santos, D., Otsuki, T., Catley, L., Tournilhac, O., Podar, K., Hideshima, T., Schlossman, R., Richardson, P., Munshi, N.C., Luqman, M. Anderson, K.C. (2005) Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Research, 65, 5898 5906.
100. Tai, Y.T., Dillon, M., Song, W., Leiba, M., Li, X.F., Burger, P., Lee, A.I., Podar, K., Hideshima, T., Rice, A.G., van Abbema, A., Jesaitis, L., Caras, I., Law, D., Weler, E., Xie, W., Richardson, P., Munshi, N.C., Mathiot, C., Avet-Loiseau, H., Afar, D.E. Anderson, K.C. (2007) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood doi:).
101. Tassone, P., Gozzini, A., Goldmacher, V., Shammas, M.A., Whiteman, K.R., Carrasco, D.R., Li, C., Allam, C.K., Venuta, S., Anderson, K.C. Munshi, N.C. (2004a) In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56 + multiple myeloma cells. Cancer Research, 64, 4629 4636.
102. Tassone, P., Goldmacher, V.S., Neri, P., Gozzini, A., Shammas, M.A., Whiteman, K.R., Hylander-Gans, L.L., Carrasco, D.R., Hideshima, T., Shringarpure, R., Shi, J., Allam, C.K., Wijdenes, J., Venuta, S., Munshi, N.C. Anderson, K.C. (2004b) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138 + multiple myeloma cells. Blood, 104, 3688 3696.
103. Tedder, T.F. Engel, P. (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunology Today, 15, 450 454.
104. Treon, S.P., Shima, Y., Preffer, F.I., Doss, D.S., Ellman, L., Schlossman, R.L., Grossbard, M.L., Belch, A.R., Pilarski, L.M. Anderson, K.C. (1999) Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. Seminars in Oncology, 26, 97 106.
105. Treon, S.P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R. Anderson, K.C. (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. Journal of Immunotherapy, 24, 263 271.
106. Treon, S.P., Pilarski, L.M., Belch, A.R., Kelliher, A., Preffer, F.I., Shima, Y., Mitsiades, C.S., Mitsiades, N.S., Szczepek, A.J., Ellman, L., Harmon, D., Grossbard, M.L. Anderson, K.C. (2002) CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. Journal of Immunotherapy, 25, 72 81.
107. Treon, S.P., Branagan, A.R., Hunter, Z., Santos, D., Tournhilac, O. Anderson, K.C. (2004) Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Annals of Oncology, 15, 1481 1483.
108. Trikha, M., Corringham, R., Klein, B. Rossi, J.F. (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clinical Cancer Research, 9, 4653 4665.
109. Weiner, L.M., Steplewski, Z., Koprowski, H., Litwin, S. Comis, R.L. (1988) Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes. Cancer Research, 48, 1042 1046.
110. Weng, W.K. Levy, R. (2001) Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood, 98, 1352 1357.
111. Westhoff, T.H., Jochimsen, F., Schmittel, A., Stoffler-Meilicke, M., Schafer, J.H., Zidek, W., Gerlich, W.H. Thiel, E. (2003) Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood, 102, 1930.
112. Witzig, T.E. (2006) Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Practice & Research. Clinical Haematology, 19, 655 668.
113. Yaccoby, S. (2005) The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clinical Cancer Research, 11, 7599 7606.
114. Yaccoby, S. Epstein, J. (1999) The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood, 94, 3576 3582.
115. Yang, J., Qian, J., Wezeman, M., Wang, S., Lin, P., Wang, M., Yaccoby, S., Kwak, L.W., Barlogie, B. Yi, Q. (2006) Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell, 10, 295 307.
116. Yoshio-Hoshino, N., Adachi, Y., Aoki, C., Pereboev, A., Curiel, D.T. Nishimoto, N. (2007) Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Research, 67, 871 875.
117. van Zaanen, H.C., Lokhorst, H.M., Aarden, L.A., Rensink, H.J., Warnaar, S.O., van der Lelie, J. van Oers, M.H. (1998) Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. British Journal Haematology, 102, 783 790.
118. Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B. Shaughnessy, J. Jr. (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood, 99, 1745 1757.
119. Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B. Shaughnessy, J.D. Jr. (2006) The molecular classification of multiple myeloma. Blood, 108, 2020 2028.
120. Zojer, N., Kirchbacher, K., Vesely, M., Hubl, W. Ludwig, H. (2006) Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leukaemia & Lymphoma, 47, 1103 1109.